MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
Identifieur interne : 002348 ( Main/Exploration ); précédent : 002347; suivant : 002349MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
Auteurs : Eva Van Rooij [États-Unis] ; Eric N. Olson [États-Unis]Source :
- Nature Reviews Drug Discovery [ 1474-1776 ] ; 2012-11.
Abstract
In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
Url:
DOI: 10.1038/nrd3864
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002491
- to stream Istex, to step Curation: 002491
- to stream Istex, to step Checkpoint: 000365
- to stream Main, to step Merge: 002373
- to stream Main, to step Curation: 002348
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles</title><author><name sortKey="Van Rooij, Eva" sort="Van Rooij, Eva" uniqKey="Van Rooij E" first="Eva" last="Van Rooij">Eva Van Rooij</name></author><author><name sortKey="Olson, Eric N" sort="Olson, Eric N" uniqKey="Olson E" first="Eric N." last="Olson">Eric N. Olson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C9EBE96CB571398A0B6A8A58993EB1D69E0A7CC1</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1038/nrd3864</idno><idno type="url">https://api.istex.fr/ark:/67375/GT4-1NR34L7K-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002491</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002491</idno><idno type="wicri:Area/Istex/Curation">002491</idno><idno type="wicri:Area/Istex/Checkpoint">000365</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000365</idno><idno type="wicri:doubleKey">1474-1776:2012:Van Rooij E:microrna:therapeutics:for</idno><idno type="wicri:Area/Main/Merge">002373</idno><idno type="wicri:Area/Main/Curation">002348</idno><idno type="wicri:Area/Main/Exploration">002348</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles</title><author><name sortKey="Van Rooij, Eva" sort="Van Rooij, Eva" uniqKey="Van Rooij E" first="Eva" last="Van Rooij">Eva Van Rooij</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>miRagen Therapeutics, 6200 Lookout Rd, Boulder, Colorado 80301</wicri:regionArea><wicri:noRegion>Colorado 80301</wicri:noRegion></affiliation></author><author><name sortKey="Olson, Eric N" sort="Olson, Eric N" uniqKey="Olson E" first="Eric N." last="Olson">Eric N. Olson</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Molecular Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390–79148</wicri:regionArea><wicri:noRegion>Texas 75390–79148</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Nature Reviews Drug Discovery</title><idno type="ISSN">1474-1776</idno><idno type="eISSN">1474-1784</idno><imprint><publisher>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</publisher><date when="2012-11">2012-11</date><biblScope unit="vol">11</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="860">860</biblScope><biblScope unit="page" to="872">872</biblScope><date type="Copyright" when="2012">2012</date></imprint><idno type="ISSN">1474-1776</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1474-1776</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Van Rooij, Eva" sort="Van Rooij, Eva" uniqKey="Van Rooij E" first="Eva" last="Van Rooij">Eva Van Rooij</name></noRegion><name sortKey="Olson, Eric N" sort="Olson, Eric N" uniqKey="Olson E" first="Eric N." last="Olson">Eric N. Olson</name><name sortKey="Olson, Eric N" sort="Olson, Eric N" uniqKey="Olson E" first="Eric N." last="Olson">Eric N. Olson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002348 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002348 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C9EBE96CB571398A0B6A8A58993EB1D69E0A7CC1
|texte= MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
}}
| This area was generated with Dilib version V0.6.33. |  |